ClinicalTrials.gg
RecruitingNCT07333612Updated Jan 12, 2026

IM Bands in Inactive Hepatic CE

An observational study in Cystic Echinococcosis, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Comparison of immunoblotting bands pattern in patients with treated versus untreated echinococcal cysts of the liver

02

Conditions studied

  • Cystic Echinococcosis

Browse trials for

03

In context

Echinococcosis

25 studies on the registry are indexed under Echinococcosis; 4 are open to participants now.

This study's planned enrollment of 100 is above the median of 45 across 18 observational studies indexed under Echinococcosis.

Browse Echinococcosis studies →

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 257 studies on the registry; 114 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients affected by cystic echinococcosis of the liver.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Only Hepatic echinococcal cysts
  • Age > 18 years
  • At leat 2 clinical evaluation

Exclusion criteria

Exclusion Criteria:

  • different location of echinococcal cysts
  • Age \< 18 years --less then 2 clinical evalutation
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Percentage of patients with spontaneously inactivated hepatic CE cysts with positive WB and RT t differente times from diagnosis.

    from 0 to 100%

    Time frame: from September 2024 to September 2026

Secondary outcomes

  1. Percentage of cysts that remaine inactive after treatment or reactivate

    from 0 to 100%

    Time frame: from september 2024 to September 2026

  2. Percentage of patients with inactivated cysts after treatment with positive WB results at different time point from the first observation of an inactive stage.

    from 0 to 100%

    Time frame: from September 2024 to September 2026

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07333612
Responsible party
Raffaella Lissandrin (Principal Investigator, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Jan 12, 2026
Start date
Sep 23, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Jan 12, 2026
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion